Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclobarbital is a barbiturate, a class of drugs known for their sedative-hypnotic properties. It has been historically used in medicine for general anesthesia and in the treatment of epilepsy. Beyond its established clinical uses, cyclobarbital has been investigated for a broad spectrum of pharmacological activities, including antioxidant, antidiabetic, anticancer, anti-nociceptive, anti-diarrheal, antipyretic, thrombolytic, anthelmintic, and antibiofilm effects. Studies have also shown its ability to induce cytochrome P450 enzymes, specifically CYP1A2 and CYP2B1/2, and it has demonstrated binding affinity to targets like cyclin-dependent kinase 2 (CDK2) and thymidylate synthase (TS) in computational analyses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cyclobarbital.